INT15002

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.37
First Reported 1991
Last Reported 2011
Negated 0
Speculated 1
Reported most in Body
Documents 17
Total Number 18
Disease Relevance 5.34
Pain Relevance 3.61

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

structural molecule activity (Gfap) extracellular matrix organization (Gfap) cytoplasm (Gfap)
Anatomy Link Frequency
brain 3
astrocytes 3
radial 1
retina 1
glial cell 1
Gfap (Mus musculus)
Pain Link Frequency Relevance Heat
Nerve growth factor 60 99.44 Very High Very High Very High
Morphine 10 96.96 Very High Very High Very High
Spinal cord 112 96.32 Very High Very High Very High
Pain 9 95.80 Very High Very High Very High
chemokine 4 92.56 High High
Central nervous system 54 91.96 High High
Opioid 1 90.36 High High
Dorsal horn 3 89.00 High High
Inflammation 58 87.60 High High
ASIC 4 87.60 High High
Disease Link Frequency Relevance Heat
Glaucoma 41 99.60 Very High Very High Very High
Targeted Disruption 49 99.38 Very High Very High Very High
Gliosis 5 99.16 Very High Very High Very High
Death 40 99.12 Very High Very High Very High
Nociception 4 99.02 Very High Very High Very High
Stab Wounds 15 98.68 Very High Very High Very High
Cytomegalovirus Infection 57 97.84 Very High Very High Very High
Infection 49 97.44 Very High Very High Very High
Pain 6 95.80 Very High Very High Very High
Ocular Hypertension 8 95.52 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Western blot analysis was used to determine the effect of the drug treatment on GFAP levels, a marker of astrocytosis [13].
Spec (determine) Regulation (effect) of GFAP associated with gliosis
1) Confidence 0.37 Published 2004 Journal J Neuroinflammation Section Body Doc Link PMC527877 Disease Relevance 0.42 Pain Relevance 0.19
GFAP was up-regulated.
Regulation (regulated) of GFAP
2) Confidence 0.35 Published 2008 Journal J Ocul Biol Dis Infor Section Body Doc Link PMC2802414 Disease Relevance 0 Pain Relevance 0
Furthermore, using transgenic mice expressing GFP under the control of a mouse GFAP promoter [27], we were able to visualize the extensive meshwork of the BG system in the ML, and found that GFAP was largely concentrated in the radial BG fibers, but not the finer lateral appendages and processes (Figure S4B).
Regulation (control) of GFAP in radial associated with targeted disruption
3) Confidence 0.35 Published 2008 Journal PLoS Biology Section Body Doc Link PMC2689695 Disease Relevance 0.10 Pain Relevance 0
When cultured in the presence of dbcAMP, cells were immunopositive for vimentin, GFAP, O4, and GalC.
Regulation (immunopositive) of GFAP
4) Confidence 0.27 Published 2010 Journal Journal of Korean Medical Science Section Body Doc Link PMC2826742 Disease Relevance 0.18 Pain Relevance 0.10
GFAP immunoreactivity and proenkephalin mRNA hybridization reaction were examined in intact glial cell preparations from neonatal mice that were cultured for 4-6 days prior to fixation.
Regulation (immunoreactivity) of GFAP in glial cell
5) Confidence 0.26 Published 1991 Journal J. Neurosci. Methods Section Abstract Doc Link 1712058 Disease Relevance 0 Pain Relevance 0.09
No vimentin-positive cells and only GFAP immunoreactivity was detected in the visual cortex (Additional file 4).
Regulation (immunoreactivity) of GFAP in cortex
6) Confidence 0.26 Published 2011 Journal Behav Brain Funct Section Body Doc Link PMC3023691 Disease Relevance 0 Pain Relevance 0
An increase in glial fibrillary acid protein (GFAP) immunoreactivity was observed in the contralateral SC at 7, 30, and 90 days after NMDA injection and in the ipsilateral SC at 7 days, while brain-derived neurotrophic factor (BDNF) expression was increased in the contralateral SC at 30 and 90 days.
Regulation (immunoreactivity) of glial fibrillary acid protein in brain
7) Confidence 0.25 Published 2009 Journal Molecular Vision Section Abstract Doc Link PMC2664844 Disease Relevance 0 Pain Relevance 0
An increase in glial fibrillary acid protein (GFAP) immunoreactivity was observed in the contralateral SC at 7, 30, and 90 days after NMDA injection and in the ipsilateral SC at 7 days, while brain-derived neurotrophic factor (BDNF) expression was increased in the contralateral SC at 30 and 90 days.
Regulation (immunoreactivity) of GFAP in brain
8) Confidence 0.25 Published 2009 Journal Molecular Vision Section Abstract Doc Link PMC2664844 Disease Relevance 0 Pain Relevance 0
GFAP immunoreactivity was increased in Müller cells from the inner to the outer limiting membranes in retina from rats with elevated intraocular pressure [37].
Regulation (immunoreactivity) of GFAP in retina associated with ocular hypertension
9) Confidence 0.25 Published 2009 Journal Molecular Vision Section Body Doc Link PMC2647972 Disease Relevance 0.99 Pain Relevance 0.16
Our results support these findings, where GFAP immunoreactivity was temporally associated with that of FGF-2 especially in SC1.
Regulation (immunoreactivity) of GFAP
10) Confidence 0.24 Published 2010 Journal Frontiers in Cellular Neuroscience Section Body Doc Link PMC2990542 Disease Relevance 0.09 Pain Relevance 0.12
A strong widespread colocalization was prominent between FGF-2 and GFAP immunoreactivity.


Regulation (immunoreactivity) of GFAP
11) Confidence 0.24 Published 2010 Journal Frontiers in Cellular Neuroscience Section Body Doc Link PMC2990542 Disease Relevance 0 Pain Relevance 0.14
At 3 days post lesion, GFAP immunoreactivity was increased in both WT and null mice, but the response was markedly abrogated in IL-1R1-null mice.
Regulation (immunoreactivity) of GFAP
12) Confidence 0.22 Published 2006 Journal J Neuroinflammation Section Body Doc Link PMC1533808 Disease Relevance 0.28 Pain Relevance 0.09
To record Ca2+ activity in astrocytes, slices were loaded with Fluo-4 and astrocytes were identified by using a transgenic animal in which astrocytes express monomeric red fluorescent protein 1 (mRFP1) under the GFAP promoter (Hirrlinger et al., 2005).
Regulation (under) of GFAP promoter in astrocytes associated with targeted disruption
13) Confidence 0.20 Published 2010 Journal The Journal of General Physiology Section Body Doc Link PMC2888059 Disease Relevance 0.10 Pain Relevance 0.24
In this work, we studied transgenic glial fibrillary acidic protein-IkappaBalpha-dn mice that selectively inactivate the classical nuclear factor kappaB pathway by overexpressing the inhibitory protein of kappaBalpha in astrocytes, under the control of glial fibrillary acidic protein promoter.
Regulation (control) of fibrillary acidic protein promoter in astrocytes associated with targeted disruption
14) Confidence 0.20 Published 2007 Journal Neuroreport Section Abstract Doc Link 17426605 Disease Relevance 0.57 Pain Relevance 0.29
On the other hand, we did not observe any change in the expression levels of intracellular GFAP, a marker for astrocytes.
Regulation (change) of GFAP in astrocytes
15) Confidence 0.20 Published 2011 Journal PLoS ONE Section Body Doc Link PMC3020957 Disease Relevance 0.72 Pain Relevance 0.06
In the present study, we assess nociceptive responses of mice that overexpressed CCL2 under control of glial fibrillary acidic protein promoter (CCL2 tg).
Regulation (control) of fibrillary acidic protein promoter associated with nociception
16) Confidence 0.19 Published 2007 Journal Neuroscience Section Abstract Doc Link 17870246 Disease Relevance 0.70 Pain Relevance 0.45
Furthermore, transgenic mice that express enhanced green fluorescent protein (EGFP) under the control of the mouse GFAP promoter displayed enhanced levels of EGFP expression after repeated treatment with morphine.
Regulation (control) of GFAP promoter associated with targeted disruption and morphine
17) Confidence 0.05 Published 2004 Journal Eur. J. Neurosci. Section Abstract Doc Link 14725643 Disease Relevance 0.26 Pain Relevance 1.21
To test this idea in a transgenic model, Pettigrew et al. [80] expressed NGF throughout the brain under control of the GFAP promoter.
Regulation (control) of GFAP promoter in brain associated with targeted disruption and nerve growth factor
18) Confidence 0.01 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2604901 Disease Relevance 0.93 Pain Relevance 0.47

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox